favipiravir - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.69 [0.28, 1.68]< 10%1 study (1/-)79.1 %some concernnot evaluable moderatecrucial-
deaths 1.07 [0.62, 1.84]< 10%5 studies (5/-)40.6 %highnot evaluable lowcrucial-
clinical improvement 1.66 [1.28, 2.15]> 10%4 studies (4/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.10 [0.58, 2.11]> 131%2 studies (2/-)61.5 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.32 [0.86, 2.03]> 170%2 studies (2/-)89.4 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.62 [1.15, 2.28]> 10%2 studies (2/-)99.7 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.23 [0.93, 1.63]> 168%5 studies (5/-)92.9 %highnot evaluable lowimportant-
hospital discharge 1.08 [0.85, 1.35]> 145%3 studies (3/-)73.2 %highnot evaluable lowimportant-
hospitalization 0.12 [0.01, 2.26]< 10%1 study (1/-)92.0 %NAnot evaluable important-
mechanical ventilation 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
viral clearance 1.54 [0.97, 2.42]> 172%6 studies (6/-)96.8 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 1.13 [0.82, 1.57]> 154%3 studies (3/-)77.1 %some concernnot evaluable moderateimportant-
viral clearance by day 14 1.30 [0.50, 3.36]> 148%2 studies (2/-)70.5 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.44 [0.78, 2.65]> 161%3 studies (3/-)87.5 %some concernnot evaluable moderateimportant-
ICU admission 1.42 [0.79, 2.55]< 10%1 study (1/-)12.0 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 2.73 [0.55, 13.60]< 10%4 studies (4/-)11.1 %some concernnot evaluable moderateimportant-
adverse events 3.33 [1.23, 9.02]< 187%5 studies (5/-)0.9 %some concernserious moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.